This title acts as a primer, giving students and newcomers to the
field an opportunity to learn about the breadth of the CNS drug
discovery. The book outlines the core processes in drug discovery
and development for CNS disorders, from evaluating drugs for
desirable efficacy, safety and pharmacokinetic features in
preclinical (using in vitro and in vivo models) and
clinical experimentation to identifying future drug targets.
Containing up-to-date experimental evidence and detailing the main
impediments in the pipeline of CNS drug discovery and development,
this is a key reference for those involved in all stages of CNS
drug discovery.
Key Features:
* Discusses in detail the key stages of CNS drug discovery,
outlining the particular requirements and obstacles for CNS
drugs
* Addresses safety concerns and future drug targets
* Provides succinct background information about the major CNS
diseases
* Examples of specific drugs are used throughout to describe the
development of a new drug from conception to clinical use and
post-market surveillance
* Primary reasons for drug failure are given for each stage
Об авторе
Dr. John Kelly, Senior Lecturer, Department of Pharmacology and Therapeutics, NUI, Galway, Ireland.